Researchers' Profiles

Larissa Mooney, M.D.

Larissa Mooney, M.D.

Principal Investigator

Dr. Larissa Mooney is a board certified addiction psychiatrist with expertise in the treatment of substance use disorders and psychiatric comorbidity. After obtaining residency training at New York University, she completed a fellowship in addiction psychiatry at Cedars-Sinai Medical Center in 2006. Dr. Mooney is an Assistant Clinical Professor of Psychiatry at UCLA and Director of the UCLA Addiction Medicine Clinic, where she supervises and teaches psychiatrists in training in both inpatient and outpatient clinical settings. She is active in the American Academy of Addiction Psychiatry (AAAP), where she serves on the Executive Board of Directors. Since joining UCLA Integrated Substance Abuse Programs in 2007, Dr. Mooney has conducted research on treatment interventions for addictive disorders and has collaborated on community training initiatives to enhance understanding of substance abuse and concomitant psychiatric illness among mental health clinicians. She is a Co-Lead Investigator for the Pacific Region Node of the NIDA Clinical Trials Network. Her interests include development of psychopharmacological and integrated treatments for addiction and advancement of substance abuse training for health care professionals.

  • Undergraduate: Cornell University, NY, B.S., Biology, 1997
  • Medical: SUNY Health Science Center at Brooklyn, NY, M.D., 2001
  • Residency: New York University, NY, Psychiatry, 2001-2005
  • Fellowship: Cedars-Sinai Medical Center, CA, Addiction, 2005-2006
  • Addiction Psychiatry
  • Psychopharmacology

Haglund, M., Mooney, L., Gitlin, M., Miotto, K., Fong, T., Tsuang, J. (in press). Vivitrol and depression: a case report and review of the literature. Addictive Disorders and Their Treatment.

Mooney, L.J., Cooper, C., London, E., Chudzynski, J., Dolezal, B., Dickerson, D., DOa, Brecht, M.L., Penante, J., & Rawson, R.A. (2014). Exercise for methamphetamine dependence: rationale, design, and methodology. Journal of Contemporary Clinical Trials 37(1):139-47.

Ling, W., Mooney, L., Torrington, M. (2013). Buprenorphine for opioid addiction. Neuropsychiatry 3(5): 535-543.

Glasner-Edwards, S., Mooney, L.J., Ang, A., Marinelli-Casey, P., Hillhouse, M., & Rawson, R. on behalf of the Methamphetamine Treatment Project Corporate Authors. (2013). Does post-traumatic stress disorder affect post-treatment methamphetamine use? Josurnal of Dual Diagnosis 9(2):123-128.

Mooney, L.J., Nielsen, S., Saxon, A., Hillhouse, M., Thomas, C., Hasson, A., Stablein, D., McCormack, J., Lindbald, R., & Ling, W. (2012). Cocaine Use Reduction with Buprenorphine (CURB): Rationale, Design, and Methodology. Journal of Contemporary Clinical Trials. 34(2):196-204.

Nielsen S., Hillhouse M., Mooney L., Fahey J, & Ling W. (2012). Comparing buprenorphine induction experience with heroin and prescription opioid users. Journal of Substance Abuse Treatment 43(3):285-90.

Ling, W., Mooney, L., & Wu, L. (2012). Advances in opioid antagonist treatment for opioid addiction. Psychiatric Clinics of North America 35(2): 297-308.

Ling, W., Mooney, L., Zhao M., Nielsen, S., Torrington, M., & Miotto, K. (2011). A selective review and commentary on emerging pharmacotherapies for opioid addiction. Journal of Substance Abuse and Rehabilitation 2: 181–188.

Ling, W., Mooney, L.J., & Hillhouse, M. (2011). Prescription opioid abuse, pain, and addiction: clinical issues and implications. Drug and Alcohol Review 30:300-5.

Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Ang, A., & Rawson, R.A. (2010). Anxiety disorders among methamphetamine dependent adults: association with treatment outcomes. The American Journal on Addictions 19(5):385-90.

Shetty, V., Mooney, L., Zigler, CM, Belin, TR, Murphy, D, and Rawson, R. (2010). Methamphetamine use is associated with increased dental disease. Journal of the American Dental Association 141:307-318.

Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R.A. (2009). Psychopathology in methamphetamine dependent adults 3 years after treatment. Drug and Alcohol Review 29:12-20.

Mooney, L.J., Glasner-Edwards, S., Marinelli-Casey, P., Hillhouse, M., Ang, A., Hunter, J., Haning, B., Colescott, P, Ling, W., & Rawson, R.A. (2009). Health conditions in methamphetamine-dependent adults 3 years after treatment. Journal of Addiction Medicine 3(3):155-163.

Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R.A. (2008). Clinical course and post-treatment outcomes of methamphetamine dependent adults with psychosis. Journal of Substance Abuse Treatment 35: 445-50.

Glasner-Edwards, S., Mooney, L.J., Marinelli-Casey, P., Hillhouse, M., Ang, A., & Rawson, R.A. (2008). Identifying methamphetamine users at risk for major depressive disorder: findings from the Methamphetamine Treatment Project at 3-year follow-up. The American Journal on Addictions, 17(2):99-102.